The Incurable Files · No. 2 Type 1 Diabetes · Beta Cells · Terrain By Jasper Vermeer · 25 July 2026
🇳🇱 Lees in het Nederlands

Type 1 Diabetes: The Zero Assumption

Here is the sentence most people with Type 1 diabetes are handed at diagnosis: your immune system has permanently destroyed your insulin-producing cells, there is no cure, and you will inject insulin for the rest of your life while managing a slow accumulation of risk. The part that goes unstated, and turns out to matter, is the assumption buried inside it — that the destruction is total, finished, and irreversible by the time you're diagnosed. The actual evidence base contains a majority of long-standing patients whose immune systems are still measurably attacking cells that, in the same patients, are still measurably producing insulin decades later. It also contains a 2025 trial where insulin dependence was eliminated entirely. None of that is fringe. All of it is published, peer-reviewed, and rarely placed next to the sentence handed down at diagnosis.

83% Trial patients insulin-free at 12 months after stem-cell islet infusion[26]
10% Still producing measurable insulin 31–40 years after diagnosis[13]
>40% Adult-onset cases initially misdiagnosed as Type 2[17]

What Actually Causes This

Type 1 diabetes is T-cell-mediated destruction of the pancreas's insulin-producing beta cells. CD4+ and CD8+ autoreactive T cells target beta-cell proteins — insulin itself, GAD65, IA-2, and ZnT8 — through direct cytotoxic attack and cytokine signaling, principally interferon-gamma, TNF-alpha, and IL-1. The four autoantibodies clinicians test for (IAA, GADA, IA-2A, ZnT8A) are markers of this process, not the weapon doing the damage — they signal that beta-cell proteins are being exposed to the immune system, and the number of them that turn positive predicts how likely progression to clinical disease is.

Genetics sets the stage heavily but doesn't finish the story. Over 90% of children who develop T1D carry the HLA-DR3-DQ2 and/or DR4-DQ8 haplotypes, and the DR3/DR4-DQ8 heterozygous genotype is the single highest-risk combination known.[2] In siblings who share both HLA haplotypes with an already-affected sibling, risk of developing islet autoimmunity reaches 63% by age 7 and 85% by age 15.[3] But most people carrying the highest-risk genotype never develop the disease — genetics loads the gun; something else has to pull the trigger.

No EBV-Sized Trigger — And That Honesty Cuts Both Ways

Multiple sclerosis has a single, near-universal, temporally-proven viral trigger (Epstein-Barr virus, 32-fold risk increase). Type 1 diabetes does not have an equivalent, and pretending otherwise would misrepresent the field. What exists instead: a meta-analysis of 56 studies found enteroviruses — Coxsackievirus B specifically — associated with T1D at an odds ratio of roughly 8 to 12.7, real but far weaker and messier than the MS finding, with individual study results ranging wildly (0.14 to 426 in one pooled dataset).[4]

The proposed mechanism — molecular mimicry — is genuinely half-confirmed. A Coxsackievirus B protein fragment (P2C) shares a six-amino-acid sequence with GAD65, and both peptides bind the same groove of the same diabetes-associated HLA molecule (HLA-DR3): real, structural, published evidence.[5] But when researchers tested actual T-cell clones from patients, the T-cells specific to the viral peptide did not cross-react with the GAD65 peptide[6] — the structural resemblance didn't translate into functional confusion at the cellular level tested. Plausible mechanism, not confirmed function.

The most honest thing happening on this question right now isn't a claim, it's a test: a Coxsackievirus B vaccine (PRV-101) completed Phase 1 safety trials in 2024, producing strong neutralizing antibodies against all five CVB serotypes.[7] It hasn't been tested for actual T1D prevention yet — that trial would take years — but it's the closest thing to a live experimental answer to "does this virus actually cause this disease" that currently exists.

Nat Rev Endocrinol (2022), DOI 10.1038/s41574-022-00688-1 · Vreugdenhil et al. (1998) — Diabetologia 41(1):40-46, PMID 9498628 · PRV-101 Phase 1, Diabetologia 2024, PMC10954874.

The part of this story that matters most for what comes later is what "destruction" actually means over time. The standard framing treats it as a one-time event, finished by diagnosis. The literature says something more specific.

The Attack Isn't Finished — It's Still Running

The first, well-known evidence that beta cells aren't wiped out overnight is the "honeymoon phase" most newly diagnosed patients experience: surviving cells regain partial function once insulin therapy relieves the initial glucotoxicity, typically for 3-12 months before it fades.[12] What's less well known is how far past that window the same basic pattern extends. A study of 144 people a median of 23 years past childhood-onset diagnosis found that among samples taken more than a decade after diagnosis, 65.2% still had at least one positive islet autoantibody, and 35.4% still had detectable endogenous C-peptide — direct evidence that both the immune attack and residual beta-cell function persist for decades in most long-standing patients, not a rare few.[14] A separate ultrasensitive-assay study found measurable insulin production in 10% of people 31 to 40 years after onset.[13]

There's a candidate mechanism for how any beta cells survive at all: in NOD mice (the standard T1D model), a resilient subpopulation of beta cells survives by partially "hiding" — lowering the autoantigen markers that make them targets while raising PD-L1, an immune checkpoint protein.[15] Human tissue shows the same PD-L1+ pattern in surviving cells, which is consistent with the same phenomenon — but that human evidence is correlational, not yet proven at the same mechanistic resolution as the mouse data. Flagged honestly: the "cells go dormant to survive" story is confirmed in mice, plausible but unconfirmed in humans.[16]

Williams, Long, Wilson et al. (2016) — Diabetologia, "Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes," PMID 27591853 · Wang, Lovejoy, Faustman (2012) — Diabetes Care 35(3):465-470, PMID 22355018 · Rui et al. (2017) — Cell Metabolism 25(3):727-738, DOI 10.1016/j.cmet.2017.01.005 (mouse) · Webster & Mirmira (2024) — Front Endocrinol, PMID 38904049.

How You Get the Diagnosis

The modern staging framework treats T1D as a three-stage process, not a single event: Stage 1 is two or more positive autoantibodies with normal blood sugar; Stage 2 is the same autoantibodies with measurable dysglycemia; Stage 3 is the symptomatic disease that gets diagnosed.[1] This staging is what made it possible to test a drug — teplizumab — in people who don't have diabetes yet, by definition.

Getting the Stage 3 diagnosis right is not as reliable as commonly assumed. In adults, T1D onset after age 30 is roughly as common as the childhood-onset form most people picture, and more than 40% of adult-onset cases are initially misclassified as Type 2 diabetes.[17] A related, adult-specific form called LADA (Latent Autoimmune Diabetes in Adults) is missed in an estimated 4-12% of adults carrying a "Type 2" label, typically because clinicians don't test antibodies in lean, non-metabolic-syndrome adults who don't fit the Type 2 profile.[18] And diagnosis is frequently a medical emergency rather than a checkup: roughly 30-38.5% of new diagnoses in the US present in diabetic ketoacidosis (DKA), rising to as high as 81% in children under two — the youngest patients are the ones most likely to be caught only once things go acutely wrong.[19]

What You're Told to Do About It

Insulin therapy replaces the missing hormone. It does nothing to the autoimmune process destroying beta cells and nothing to restore beta-cell mass — this isn't a criticism, it's simply what insulin is for, and it's the actual mechanical basis of "manage it for life."

Immunotherapy at Diagnosis — Real Wins, One Real Catch, and One Clean Failure

Teplizumab (anti-CD3) has the two most-cited results in this field, and both need their caveats stated plainly. In at-risk relatives with Stage 2 disease, it delayed progression to clinical diabetes from a median of 24.4 months to 48.4 months — roughly two years — and 57% remained diabetes-free at trial's end versus 28% on placebo.[20] That's a real delay, not a cure — most participants still progressed eventually. In newly diagnosed patients, the follow-up PROTECT trial found significantly better preserved insulin production (C-peptide) at 78 weeks — but the clinically-felt outcomes, insulin dose and blood sugar control, only trended favorably without reaching statistical significance.[21] A real biomarker win; not yet a real day-to-day win.

Other immune-targeted trials round out an honestly mixed picture: golimumab (anti-TNF) and low-dose anti-thymocyte globulin both significantly preserved C-peptide and improved HbA1c in randomized trials.[23][24] Verapamil — a decades-old, cheap, repurposed blood pressure drug — improved insulin production and lowered hypoglycemia rates via an unrelated calcium-channel mechanism.[25] Against that: two separate, well-powered trials blocking IL-1 (canakinumab and anakinra) found no effect on beta-cell decline at all, despite being safe.[22] The honest takeaway isn't "block inflammation and beta cells recover" — it's that specific immune pathways matter and others don't, and nobody gets to skip the trial data to find out which is which.

Herold et al. (2019) — NEJM 381(7):603-613, PMID 31180194 · Ramos, Dayan, Chatenoud et al. (2023, PROTECT) — NEJM 389(23):2151-2161, PMID 37861217 · Quattrin et al. (2020, T1GER) — NEJM 383(21):2007-2017, PMID 33207093 · Haller et al. (2019) — Diabetes 68(6):1267-1276, PMID 30967424 · Ovalle et al. (2018) — Nat Med 24:1108-1112, PMID 29988125 · IL-1 antagonism trials (2013) — Lancet, PMID 23562090.

Closed-loop insulin pumps ("artificial pancreas" systems) genuinely improve glucose control — 10-25 percentage points more time in target range in recent meta-analyses. That's real engineering, worth having. It's also worth being precise about what it is: excellent glucose management, not disease modification. It does nothing for the autoimmune process or beta-cell mass, and presenting it as "the ceiling of what's possible" for T1D quietly conflates two different categories of intervention.

What They Don't Usually Mention

If beta-cell destruction is often incomplete rather than total, and if immune-targeted drugs can partially preserve function, the obvious next question is whether anything has gone further — toward actually restoring what's lost. As of 2025, the answer is a qualified yes.

VX-880 — The Trial Where Insulin Wasn't Needed Anymore

A 2025 trial infused stem-cell-derived, fully differentiated pancreatic islet cells into 12 adults with T1D and impaired awareness of dangerously low blood sugar. At 12 months, 10 of 12 participants (83%) no longer required exogenous insulin at all. Average daily insulin use across the group dropped 92%. Time in target glucose range exceeded 90%. Severe hypoglycemic events dropped to zero, from multiple per participant beforehand.[26]

This is the strongest functional-reversal signal anywhere in this article, and the caveats matter as much as the result: 12 people, no placebo group, one year of follow-up, and — critically — every participant needs ongoing systemic immunosuppression to keep their immune system from attacking the new cells the same way it attacked the original ones. That's a real, serious tradeoff, not a footnote. This isn't an accessible therapy yet. It is, as of this writing, real human proof that "beta-cell loss is permanent and total" is false as a general statement about this disease.

Reichman et al. (2025) — NEJM, DOI 10.1056/NEJMoa2506549 (Vertex VX-880/zimislecel, Phase 1/2).

Smaller, more accessible data points, reported at the strength they deserve: a small, non-randomized low-carbohydrate diet study found HbA1c drop from 7.7% to 7.1% and a 25% reduction in daily insulin use over months — promising, but not yet RCT-confirmed. The TRIGR trial directly tested the popular "cow's milk protein triggers T1D" hypothesis by randomizing high-risk infants to hydrolyzed formula — and found no difference in eventual T1D risk, a genuine myth-correction, even though a subtler dose-response association with milk antibodies persisted in secondary analysis.[9] Gluten-timing research is genuinely contradictory across studies — some finding earlier exposure raises risk, others finding later exposure does[10] — an honestly unresolved question, not a clean "avoid X" story. Gut-microbiome data points the same honest direction: the large TEDDY study found children who avoided T1D had more short-chain-fatty-acid-producing gut bacteria, but the signal wasn't consistent across the study's different geographic sites — real, not yet reducible to a specific fix.[8] Vitamin D shows a similar pattern: meta-analyses find a protective association in case-control data that weakens or disappears in cohort studies — the kind of cohort-vs-case-control discordance that's a real red flag for reverse causation, not a reason to stop taking vitamin D for general health.[11]

The Terrain Argument

Three separate, independently-documented findings point at the same structural gap. First: the autoimmune attack is frequently still active years and decades into the disease, not a one-time event finished at diagnosis.[14] Second: gut permeability — measured through the protein zonulin — is elevated a mean of 3.5 years before T1D onset in prospective data, meaning a compromised gut barrier precedes the attack rather than following it.[28] Third, and newest: a 2025 study found that efficient clearance of dying beta cells by a specific macrophage type produces long-term suppression of the autoimmune process itself in mice — while poorly cleared cell debris does the opposite, feeding a broadening attack (epitope spreading) that's the actual reason patients often go from one positive autoantibody to several within 6-12 months of the first.[27]

Put together, that's a three-part gap standard treatment doesn't touch: an upstream gut-barrier problem, an ongoing cytokine attack on the cells that are still there, and a debris-clearance step that determines whether the attack stays contained or spreads. Insulin therapy addresses none of these — it was never designed to. That gap, not a cure claim, is what the rest of this protocol is built around.

The Protocol — Built From the Gap, Not Around It

The Beta Cell Shield — Guduchi and Quercetin

This is the core of the protocol, and it rests on two independent findings converging on the same exact mechanism. Guduchi (Tinospora cordifolia) dose-dependently protects insulin-producing cells against IL-1β and interferon-gamma — the specific cytokines T-cells use to kill beta cells — while preserving insulin secretion.[29] Quercetin protects the same cell type against the same two cytokines through the same mitochondrial/NF-κB pathway, in a fully separate study.[30] Both findings come from cell-culture studies, not human T1D trials — real mechanism, not yet clinical proof, and stated as such rather than oversold.

Quercetin is paired with onion rather than taken as an isolated compound for a specific, unglamorous reason: onion-derived quercetin glucosides are absorbed at roughly 52% in humans, versus about 20% for the free aglycone form most supplements contain — a genuine 2.5x bioavailability gain from the delivery form itself, with no enzyme inhibition and no added interaction risk.[31]

Kumar et al. (2019) — Phytother Res, PMID 31385371 · Int J Mol Med (2012), PMID 23138875 · Hollman et al. (1997) — FEBS Lett 418(1-2):152-156, PMID 9414116.

Push Back the Attacker — Astragalus and Rehmannia

In NOD mice — the standard T1D animal model — a formula containing Astragalus and Rehmannia increased protective regulatory T-cells and measurably reduced T-cell infiltration into the islets of Langerhans themselves, the actual site of the attack.[32] Stated plainly: this proves the ten-herb formula as a whole, not these two herbs in isolation. They're used here because they're the same two herbs independently flagged for autoimmune modulation — a real, if indirect, convergence, not a claim of proof beyond what the study shows.

Wang, Xie, Liang, Zeng, Dai (2017) — Oncotarget 8(36):60201-60209, PMID 28947964.
Seal the Gut Gate — Marshmallow Root, Slippery Elm Targets the upstream permeability finding directly Zonulin elevation precedes T1D onset by 3.5 years on average.[28] These mucilage plants have well-established use protecting the gut lining generally — proven mechanism target, not a T1D-specific trial. Both delay absorption of other oral medication.
Prevent Recirculation — Yellow Sweet Clover, Cleaver Mechanism proven, herb evidence honestly absent A 2025 Nature paper proved efficient beta-cell-debris clearance suppresses autoimmunity long-term in mice.[27] No herb has direct published evidence for enhancing this specific process — that research doesn't exist yet. These are traditional lymphatic-clearance herbs, included on mechanism plausibility alone, stated honestly as a gap rather than dressed up as proven.

Before You Start

Insulin is never optional, and this protocol replaces it under no circumstance, at no dose. Unlike disease-modifying therapy for other conditions, missing insulin in Type 1 Diabetes leads to life-threatening diabetic ketoacidosis within hours to days. Never stop, reduce, or delay insulin because of anything in this article. Never adjust insulin dosing based on this protocol without your endocrinologist or diabetes team.

Nearly every ingredient here can lower blood sugar — Guduchi, quercetin/onion, Astragalus, and Rehmannia all have documented glucose-lowering activity. Combined with insulin, that's a real hypoglycemia risk, not a theoretical one. Introduce one step at a time and monitor glucose closely.

Guduchi and Astragalus are immunomodulatory. Avoid, or discuss with your doctor first, if you're on immunosuppressive medication or enrolled in an immunotherapy trial such as teplizumab.

Yellow Sweet Clover contains coumarins that convert to the potent anticoagulant dicoumarol if improperly dried. Never combine with blood thinners or use before surgery, and buy only from a reliable source.

Full dosing, sourcing and step-by-step application: see the protocol page linked below.

The Sovereign Position

"No cure" is true. "Nothing can be done between diagnosis and complications" is not the same claim, and the evidence doesn't support it. What's actually true: beta-cell destruction is frequently incomplete and ongoing rather than total and finished, gut permeability measurably precedes the attack rather than following it, and the field's newest finding shows that how efficiently the body clears its own cellular debris determines whether the immune attack stays contained or spreads to new targets. None of that is a botanical cure, and none of it replaces insulin for a single day.

What it does mean is that the standard toolkit — replace the hormone, wait for complications, manage them when they arrive — addresses only the symptom of a three-part problem, not the mechanism driving it. Protect the gut barrier that failed years before diagnosis. Shield the beta cells still standing from the exact cytokines still attacking them. Support the immune brakes that are supposed to stop the attack and don't. That's a different instruction than "manage it for life," and as of the 2025 findings in this article, it's the one closer to what the evidence actually shows.

The diagnosis is real. The zero isn't automatic.

T1D involves real, autoimmune-driven destruction of real tissue — nothing here disputes that, and nothing here replaces insulin. But "your beta cells will reach zero" has quietly hardened from a common outcome into an assumed law of the disease, and the literature doesn't support that hardening. A third of long-standing patients still measurably produce insulin. A 2025 trial eliminated the need for it entirely, in a small but real human trial. The standard treatment paradigm targets the symptom of a three-part problem. Knowing where the other two parts are isn't false hope — it's reading the rest of the paper.

The full protocol referenced above, with dosing and application detail.

The Beta Cell Defense Protocol → Architecture of Disease →

Sources

  1. Insel RA, Dunne JL, Atkinson MA, et al. "Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association." Diabetes Care. 2015;38(10):1964-1974. PMID 26404926
  2. "Genetics of Type 1 Diabetes." Rev Diabet Stud. PMC4874193
  3. "No extreme genetic risk for type 1 diabetes among DR3/4-DQ8 siblings." PMID 21388358
  4. "Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus." Nat Rev Endocrinol. 2022. DOI 10.1038/s41574-022-00688-1
  5. Vreugdenhil GR, Geluk A, Ottenhoff TH, et al. "Molecular mimicry in diabetes mellitus: the homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 binds HLA-DR3." Diabetologia. 1998;41(1):40-46. PMID 9498628
  6. Schloot NC, Willemen SJ, et al. "Molecular mimicry in type 1 diabetes mellitus revisited: T-cell clones to GAD65 peptides with sequence homology to Coxsackie or proinsulin peptides do not crossreact." J Autoimmun.
  7. "Coxsackievirus B vaccine (PRV-101), Phase 1 safety and immunogenicity." Diabetologia. 2024. PMC10954874
  8. "The TEDDY study: gut microbiome and islet autoimmunity." Nature. 2018. PMID 30356183
  9. TRIGR Study Group. "Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes." JAMA. 2018. PMID 29297078
  10. BABYDIET study, gluten introduction timing, Diabetes Care. PMID 21515839 · early gluten exposure and islet autoantibodies, PMID 25038720
  11. Vitamin D intake and type 1 diabetes risk, meta-analysis. PMID 24036529
  12. Partial clinical remission ("honeymoon phase") duration in pediatric T1D. Pediatr Diabetes. DOI 10.1111/j.1399-543X.2006.00155.x
  13. Wang L, Lovejoy NF, Faustman DL. "Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay." Diabetes Care. 2012;35(3):465-470. PMID 22355018
  14. Williams GM, Long AE, Wilson IV, et al. "Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes." Diabetologia. 2016. PMID 27591853
  15. Rui J, Deng S, Arazi A, et al. "β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice." Cell Metab. 2017;25(3):727-738. DOI 10.1016/j.cmet.2017.01.005 (mouse model)
  16. Webster CM, Mirmira RG. "Beta cell dedifferentiation in type 1 diabetes: sacrificing function for survival?" Front Endocrinol. 2024. PMID 38904049
  17. Thomas NJ, Jones SE, Weedon MN, et al. "Frequency and phenotype of type 1 diabetes in the first six decades of life." Lancet Diabetes Endocrinol. 2018;6(2):122-129. DOI 10.1016/S2213-8587(17)30362-5
  18. "Latent Autoimmune Diabetes in Adults: Diagnostic and Therapeutic Challenges." PMC12522475
  19. SEARCH for Diabetes in Youth Study, DKA prevalence at diagnosis. Diabetes Care. 2021. PMC8323183
  20. Herold KC, Bundy BN, Long SA, et al. "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes." N Engl J Med. 2019;381(7):603-613. PMID 31180194
  21. Ramos EL, Dayan CM, Chatenoud L, et al. (PROTECT trial) N Engl J Med. 2023;389(23):2151-2161. PMID 37861217
  22. IL-1 antagonism (canakinumab, anakinra) trials in new-onset T1D. Lancet. 2013. PMID 23562090
  23. Quattrin T, Haller MJ, Steck AK, et al. (T1GER trial) "Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes." N Engl J Med. 2020;383(21):2007-2017. PMID 33207093
  24. Haller MJ, Long SA, Blanchfield JL, et al. "Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide... in New-Onset Type 1 Diabetes." Diabetes. 2019;68(6):1267-1276. PMID 30967424
  25. Ovalle F, Grimes T, Xu G, et al. "Verapamil and beta cell function in adults with recent-onset type 1 diabetes." Nat Med. 2018;24:1108-1112. PMID 29988125
  26. Reichman TW, et al. "Stem-Cell-Derived Islet Cells (Zimislecel/VX-880) in Type 1 Diabetes." N Engl J Med. 2025. DOI 10.1056/NEJMoa2506549
  27. Zakharov PN, Chowdhury CS, Peterson OJ, et al. "Efferocytic remodelling of pancreatic islet macrophages by limited β-cell death." Nature. 2025;647:1014-1024. PMID 41034589
  28. Sapone A, de Magistris L, Pietzak M, et al. "Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives." Diabetes. 2006;55(5):1443-1449. PMID 16644703
  29. Kumar V, et al. "Tinospora cordifolia preserves pancreatic beta cells and enhances glucose uptake." Phytother Res. 2019. PMID 31385371
  30. "Quercetin and quercitrin protect against cytokine-induced injuries in RINm5F β-cells via the mitochondrial pathway and NF-κB signaling." Int J Mol Med. 2012. PMID 23138875
  31. Hollman PC, van Trijp JM, Buysman MN, et al. "Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man." FEBS Lett. 1997;418(1-2):152-156. PMID 9414116
  32. Wang Y, Xie Q, Liang CL, Zeng Q, Dai Z. "Chinese medicine Ginseng and Astragalus granules ameliorate autoimmune diabetes by upregulating regulatory T cells." Oncotarget. 2017;8(36):60201-60209. PMID 28947964

The Reference

500 botanicals — each with documented mechanisms, dosages, and synergy protocols. The complete reference for sovereign health practice.

The 500 Most Powerful Botanicals →